Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5

References

• Rothenberg ME. Eosinophilia. N. Engl. J. Med. 338(22), 1592–1600 (1998).
   PubMed Web of Science ®Google Scholar
• Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu. Rev. Med.54,169–184 (2003).
   PubMed Web of Science ®Google Scholar
• Ehrlich P. Ueber die specifischen granulationen des blut. Arch. Anat. Physiol. Lpz. 571–579 (1879).
   Google Scholar
• Stilman R. A case of myeloid leukaemia with predominance of eosinophilic cells. Med. Rec. 81, 594–595 (1912).
   Google Scholar
• Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann. Intern. Med. 68(6), 1220–1229 (1968).
   PubMed Web of Science ®Google Scholar
• Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54(1), 1–27 (1975).
   PubMed Web of Science ®Google Scholar
• Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N. Engl. J. Med.341(15), 1112–1120 (1999).
   PubMed Web of Science ®Google Scholar
• Roufosse F, Schandene L, Sibille C et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br. J. Haematol.109(3), 540–548 (2000).
   PubMed Web of Science ®Google Scholar
• Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 59(7), 673–689 (2004).
   PubMed Web of Science ®Google Scholar
• Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J. Allergy Clin. Immunol.113(1), 11–28 (2004).
   PubMed Web of Science ®Google Scholar
• Bogenrieder T, Griese DP, Schiffner R et al. Wells’ syndrome associated with idiopathic hypereosinophilic syndrome. Br. J. Dermatol.137(6), 978–982 (1997).
   PubMedGoogle Scholar
• Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J. Rheumatol. 11(5), 569–570 (1984).
   PubMed Web of Science ®Google Scholar
• Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood79(12), 3101–3109 (1992).
   PubMed Web of Science ®Google Scholar
• McKenzie AN, Ely B, Sanderson CJ. Mutated interleukin-5 monomers are biologically inactive. Mol. Immunol. 28(1–2), 155–158 (1991).
   PubMed Web of Science ®Google Scholar
• Minamitake Y, Kodama S, Katayama T et al. Structure of recombinant human interleukin 5 produced by Chinese hamster ovary cells. J. Biochem. 107(2), 292–297 (1990).
   PubMed Web of Science ®Google Scholar
• Tavernier J, Devos R, Cornelis S et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 66(6), 1175–1184 (1991).
   PubMed Web of Science ®Google Scholar
• Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell66(6), 1165–1174 (1991).
   PubMed Web of Science ®Google Scholar
• Murata Y, Takaki S, Migita M et al. Molecular cloning and expression of the human interleukin 5 receptor. J. Exp. Med. 175(2), 341–351 (1992).
   PubMed Web of Science ®Google Scholar
• Simon HU, Yousefi S, Schranz C et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J. Immunol. 158(8), 3902–3908 (1997).
   PubMed Web of Science ®Google Scholar
• Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73(6), 1504–1512 (1989).
   PubMed Web of Science ®Google Scholar
• Owen WF, Rothenberg ME, Petersen J et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J. Exp. Med. 170(1), 343–348 (1989).
   PubMed Web of Science ®Google Scholar
• Owen WF Jr, Petersen J, Sheff DM et al. Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc. Natl Acad. Sci. USA 87(21), 8647–8651 (1990).
   PubMed Web of Science ®Google Scholar
• Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood75(1), 13–16 (1990).
   PubMed Web of Science ®Google Scholar
• Inoue C, Ichikawa A, Hotta T, Saito H. Constitutive gene expression of interleukin-5 in Kimuras disease. Br. J. Haematol. 76(4), 554–555 (1990).
   PubMedGoogle Scholar
• Chen H, Thompson LD, Aguilera NS, Abbondanzo SL. Kimura disease: a clinicopathologic study of 21 cases. Am. J. Surg. Pathol. 28(4), 505–513 (2004).
   PubMed Web of Science ®Google Scholar
• Hamid Q, Azzawi M, Ying S et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J. Clin. Invest. 87(5), 1541–1546 (1991).
   PubMed Web of Science ®Google Scholar
• Wang JM, Rambaldi A, Biondi A et al. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur. J. Immunol. 19(4), 701–705 (1989).
   PubMed Web of Science ®Google Scholar
• Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J. Exp. Med. 182(4), 1169–1174 (1995).
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Ownbey R, Mehlhop PD et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol. Med. 2(3), 334–348 (1996).
   PubMed Web of Science ®Google Scholar
• Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J. Clin. Invest. 78(6), 1701–1706 (1986).
   PubMed Web of Science ®Google Scholar
• Kita H, Gleich GJ. Chemokines active on eosinophils: potential roles in allergic inflammation. J. Exp. Med. 183(6), 2421–2426 (1996).
   PubMed Web of Science ®Google Scholar
• Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy59(8), 793–805 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Nagata M, Sakamoto Y. CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1. Ann. Allergy Asthma Immunol. 94(2), 292–300 (2005).
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Owen WF Jr, Silberstein DS et al. Eosinophils cocultured with endothelial cells have increased survival and functional properties. Science 237(4815), 645–647 (1987).
   PubMed Web of Science ®Google Scholar
• Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J. Allergy Clin. Immunol. 112(4), 653–665 (2003).
   PubMed Web of Science ®Google Scholar
• Kita H. The eosinophil: a cytokine-producing cell? J. Allergy Clin. Immunol. 97(4), 889–892 (1996).
   PubMedGoogle Scholar
• Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am. J. Respir. Cell Mol. Biol. 21(3), 291–295 (1999).
   PubMed Web of Science ®Google Scholar
• Dulkys Y, Schramm G, Kimmig D et al. Detection of mRNA for eotaxin-2 and eotaxin-3 in human dermal fibroblasts and their distinct activation profile on human eosinophils. J. Invest. Dermatol. 116(4), 498–505 (2001).
   PubMed Web of Science ®Google Scholar
• Shinagawa K, Trifilieff A, Anderson GP. Involvement of CCR3-reactive chemokines in eosinophil survival. Int. Arch. Allergy Immunol. 130(2), 150–157 (2003).
   PubMed Web of Science ®Google Scholar
• Luster AD. Antichemokine immunotherapy for allergic diseases. Curr. Opin. Allergy Clin. Immunol. 1(6), 561–567 (2001).
   PubMedGoogle Scholar
• Fauci AS, Harley JB, Roberts WC et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann. Intern. Med. 97(1), 78–92 (1982).
   PubMed Web of Science ®Google Scholar
• Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. J. Allergy Clin. Immunol. 113(1), 50–58 (2004).
   PubMedGoogle Scholar
• Tai PC, Ackerman SJ, Spry CJ et al. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet1(8534), 643–647 (1987).
   PubMed Web of Science ®Google Scholar
• Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 83(10), 2759–2779 (1994).
   PubMed Web of Science ®Google Scholar
• Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann. Thorac. Surg. 46(5), 570–571 (1988).
   PubMedGoogle Scholar
• Lefebvre C, Bletry O, Degoulet P et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann. Med. Intern.140(4), 253–257 (1989).
   PubMedGoogle Scholar
• Alfaham MA, Ferguson SD, Sihra B, Davies J. The idiopathic hypereosinophilic syndrome. Arch. Dis. Child. 62(6), 601–613 (1987).
   PubMed Web of Science ®Google Scholar
• Olson TA, Virmani R, Ansinelli RA et al. Cardiomyopathy in a child with hypereosinophilic syndrome. Pediatr. Cardiol. 3(2), 161–169 (1982).
   PubMedGoogle Scholar
• Rioux JD, Stone VA, Daly MJ et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31–q33. Am. J. Hum. Genet. 63(4), 1086–1094 (1998).
   PubMedGoogle Scholar
• Klion AD, Law MA, Riemenschneider W et al. Familial eosinophilia: a benign disorder? Blood103(11), 4050–4055 (2004).
   PubMed Web of Science ®Google Scholar
• Durham SR, Kay AB. Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin. Allergy 15(5), 411–418 (1985).
   PubMedGoogle Scholar
• Molinier S, Chaudier B, Kraemer P et al. Diagnostic and treatment of hypereosinophilia upon return from the tropics: 102 patients. Med. Trop. 58(4 Suppl.), 499–502 (1998).
   PubMedGoogle Scholar
• Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br. J. Haematol. 121(2), 203–223 (2003).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Jacobson E, Hamza S, Skelton H. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses. Arch. Dermatol.140(5), 584–588 (2004).
   PubMedGoogle Scholar
• Bain BJ. Eosinophilia--idiopathic or not? N. Engl. J. Med. 341(15), 1141–1143 (1999).
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van Lom K, Lowenberg B. Eosinophilia and granulocytic dysplasia terminating in acute myeloid leukaemia after 24 years. Br. J. Haematol. 95(3), 531–534 (1996).
   PubMed Web of Science ®Google Scholar
• Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201–1214 (2003).
   PubMed Web of Science ®Google Scholar
• Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am. J. Hematol. 77(1), 82–85 (2004).
   Google Scholar
• Cools J, Quentmeier H, Huntly BJ et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood103(7), 2802–2805 (2004).
   PubMed Web of Science ®Google Scholar
• Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr. Opin. Hematol. 11(1), 51–57 (2004).
   PubMed Web of Science ®Google Scholar
• Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 93(5), 1651–1657 (1999).
   PubMed Web of Science ®Google Scholar
• Kitano K, Ichikawa N, Shimodaira S et al. Eosinophilia associated with clonal T-cell proliferation. Leuk. Lymphoma. 27(3–4), 335–342 (1997).
   PubMed Web of Science ®Google Scholar
• Simon HU, Yousefi S, Dommann-Scherrer CC et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J. Exp. Med. 183(3), 1071–1082 (1996).
   PubMedGoogle Scholar
• Simon HU, Plotz SG, Simon D, Dummer R, Blaser K. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int. Arch. Allergy Immunol. 124(1–3), 242–245 (2001).
   PubMedGoogle Scholar
• Bank I, Amariglio N, Reshef A et al. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk. Lymphoma. 42(1–2), 123 (2001).
   PubMedGoogle Scholar
• Klion AD, Noel P, Akin C et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101(12), 4660–4666 (2003).
   PubMed Web of Science ®Google Scholar
• Klion AD, Robyn J, Akin C et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103(2), 473–478 (2004).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Ketterling RP, Brockman SR et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102(9), 3093–3096 (2003).
   PubMed Web of Science ®Google Scholar
• Roumier AS, Grardel N, Lai JL et al.. Hypereosinophilia with abnormal T cells, trisomy 7 and elevated TARC serum level. Haematologica 88(7), ECR24 (2003).
   PubMedGoogle Scholar
• Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta. Haematol. 114(1), 41–51 (2005).
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP, Escribano L et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 25(7), 603–625 (2001).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Reeder T, Porrata LF et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101(9), 3391–3397 (2003).
   PubMed Web of Science ®Google Scholar
• Furitsu T, Tsujimura T, Tono T et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92(4), 1736–1744 (1993).
   PubMed Web of Science ®Google Scholar
• Braun CM, Huang SK, Bashian GG et al. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J. Allergy Clin. Immunol. 100(3), 400–407 (1997).
   PubMedGoogle Scholar
• Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann. Intern. Med. 121(9), 648–653 (1994).
   PubMed Web of Science ®Google Scholar
• Demiroglu H, Dundar S. Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br. J. Haematol. 97(4), 928–930 (1997).
   PubMed Web of Science ®Google Scholar
• Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J. Dermatol. 27(2), 110–115 (2000).
   PubMedGoogle Scholar
• Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am. J. Pediatr. Hematol. Oncol. 14(4), 348–351 (1992).
   PubMedGoogle Scholar
• Jabbour E, Verstovsek S, Giles F et al. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3), 541–546 (2005).
   PubMedGoogle Scholar
• Cooper MA, Akard LP, Thompson JM, Dugan MJ, Jansen J. Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. Am. J. Hematol. 78(1), 33–36 (2005).
   PubMed Web of Science ®Google Scholar
• Schandene L, Del Prete GF, Cogan E et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J. Clin. Invest. 97(2), 309–315 (1996).
   PubMed Web of Science ®Google Scholar
• Schandene L, Roufosse F, de Lavareille A et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 96(13), 4285–4292 (2000).
   PubMed Web of Science ®Google Scholar
• Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L. Alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood 85(8), 2284–2285 (1995).
   PubMed Web of Science ®Google Scholar
• Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alpha. J. Allergy Clin. Immunol. 94(6), 1318–1326 (1994).
   PubMed Web of Science ®Google Scholar
• Elsner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88(12), 4684–4693 (1996).
   PubMed Web of Science ®Google Scholar
• Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 54(1), 11–29 (2005).
   PubMed Web of Science ®Google Scholar
• Dodero A, Carrabba M, Milani R et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp. Hematol. 33(8), 920–927 (2005).
   PubMed Web of Science ®Google Scholar
• Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br. J. Haematol.127(5), 477 (2004).
   Google Scholar
• Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br. J. Haematol.124(4), 558–559 (2004).
   PubMedGoogle Scholar
• Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics 99(4), 630–633 (1997).
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359(9317), 1577–1578 (2002).
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1), 100–104 (1996).
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuvelkar R, Murgolo NJ et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int. Immunol. 11(12), 1935–1944 (1999).
   Google Scholar
• Zia-Amirhosseini P, Minthorn E, Benincosa LJ et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J. Pharmacol. Exp. Ther. 291(3), 1060–1067 (1999).
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112(7), 1029–1036 (2003).
   Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167(2), 199–204 (2003).
   PubMed Web of Science ®Google Scholar
• Kips JC, O'Connor BJ, Langley SJ et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit.Care Med. 167(12), 1655–1659 (2003).
   PubMed Web of Science ®Google Scholar
• Garrett JK, Jameson SC, Thomson B et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol. 113(1), 115–119 (2004).
   PubMed Web of Science ®Google Scholar
• Plotz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N. Engl. J. Med. 349(24), 2334–2339 (2003).
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60(5), 693–696 (2005).
   PubMed Web of Science ®Google Scholar
• Klion AD, Law MA, Noel P et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103(8), 2939–2941 (2004).
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol. 108(2), 250–257 (2001).
   PubMedGoogle Scholar
• Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur. Respir. J. 21(5), 799–803 (2003).
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2144–2148 (2000).
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J. Allergy Clin. Immunol. 108(4), 503–508 (2001).
   PubMed Web of Science ®Google Scholar
• Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. Am. J. Respir. Crit. Care Med. 167(12), 1586–1587 (2003).
   PubMed Web of Science ®Google Scholar
• Liu LY, Sedgwick JB, Bates ME et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J. Immunol. 169(11), 6452–6458 (2002).
   PubMed Web of Science ®Google Scholar
• Gregory B, Kirchem A, Phipps S et al. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J. Immunol. 170(11), 5359–5366 (2003).
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Flood-Page P, Sehmi R et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 111(4), 714–719 (2003).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Prussin C, Martin B et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J. Allergy Clin. Immunol. 114(6), 1449–1455 (2004).
   PubMed Web of Science ®Google Scholar